AstraZeneca: EU approves Ultomiris for myasthenia gravis
(CercleFinance.com) - AstraZeneca announced on Friday that the European Union has approved Ultomiris (ravulizumab), its treatment for generalised myasthenia gravis, a rare autoimmune disease that disrupts communication between nerves and muscles.
The biopharmaceutical company says that Brussels' nod is for the drug to be used as adjunctive therapy in adult patients expressing anti-acetylcholine receptor antibodies.
The company said that the decision marks the first and only authorisation of a long-lasting inhibitory antibody targeting the C5 fraction of complement in the treatment of the disease.
This therapeutic approach was developed by Alexion, AstraZeneca's new rare disease subsidiary.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The biopharmaceutical company says that Brussels' nod is for the drug to be used as adjunctive therapy in adult patients expressing anti-acetylcholine receptor antibodies.
The company said that the decision marks the first and only authorisation of a long-lasting inhibitory antibody targeting the C5 fraction of complement in the treatment of the disease.
This therapeutic approach was developed by Alexion, AstraZeneca's new rare disease subsidiary.
Copyright (c) 2022 CercleFinance.com. All rights reserved.